XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
OVERLAYS
Fund
Benchmark
3Y · NAV total return · GBP
Pictet - Biotech R EUR: holdings, performance and fees
1Y return+59.1%
3Y return+80.5%
5Y return+51.0%
OCF (ongoing charge)2.70%
Top 10 holdings
| Holding | Weight |
|---|---|
| ARGENX SE | 4.4% |
| REVOLUTION MEDICINES INC | 4.3% |
| Insmed Inc Ord | 4.0% |
| BRIDGEBIO PHARMA, INC. | 3.5% |
| ROIVANT SCIENCES LTD. | 3.5% |
| BIOGEN INC. | 3.4% |
| VERTEX PHARMACEUTICALS INCORPORATED | 3.3% |
| UNITED THERAPEUTICS CORPORATION | 3.3% |
| AMGEN INC. | 3.2% |
| CYTOKINETICS, INCORPORATED | 2.9% |
Top sectors
- Inflammatory & immune68.7%
- Orphan Drugs19.9%
- Emerging Technologies9.9%
- Cash and equivalents1.4%
Top countries
- United States90.8%
- Belgium4.4%
- France2.5%
- Cash and equivalents1.4%
- Denmark0.9%
Holdings, sector and country weightings and performance as reported by FE fundinfo. Weightings are a percentage of the portfolio and may not sum to 100.
AI FORECAST · 12-MONTH
Powered by Claude
FREE PREVIEW
Sign up free to unlock the full AI analysis →
UP—
PREMIUM
PREMIUM
Positives
Risks
600 adviser votes
Upgrade for full forecast →
This is an illustrative, model-generated scenario based on stated assumptions. It is not a prediction, a forecast of actual returns, or investment advice. Outcomes may differ materially. Past performance is not a guide to future returns. Capital is at risk.
PORTFOLIO BREAKDOWN